Michelle H. Chan-Cortés

Michelle H. Chan-Cortés

Auto-generated profile, based on publicly available information

Michelle H. Chan-Cortés

MindMaze, Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2018 in Journal of the American Statistical Association
Verified
Journal Article
Closed access
DBDaniel Backenroth
Daniel Backenroth
JGJeff Goldsmith
Jeff Goldsmith
MHMichelle D. Harran
Michelle D. Harran
JCJuan C. Cortes
Juan C. Cortes
JKJohn W. Krakauer
John W. Krakauer
TKTomoko Kitago
Tomoko Kitago
We propose a novel method for estimating population-level and subject-specific effects of covariates on the variability of functional data. We extend the functional principal components analysis framework by modeling the variance of principal component scores as a function of covariates and subject-specific random effects. In a setting where principal components are largely invariant across subjects and covariate values, modeling the variance of these scores provides a flexible and interpretable way to explore factors that affect the variability of functional data. Our work is motivated by a novel dataset from an experiment assessing upper extremity motor control, and quantifies the reduction in movement variability associated with skill learning. The proposed methods can be applied broadly to understand movement variability, in settings that include motor learning, impairment due to injury or disease, and recovery. Supplementary materials for this article are available online.

1 January 2020 in Experimental Neurology
Verified
Journal Article
Closed access
SDSarah E. Dougherty
Sarah E. Dougherty
TKTymoteusz J. Kajstura
Tymoteusz J. Kajstura
YJYunju Jin
Yunju Jin
MCMichelle H. Chan-Cortés
Michelle H. Chan-Cortés
AKAkhil Kota
Akhil Kota
DLDavid J. Linden
David J. Linden

30 March 2023 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
LKLingling Kong
Lingling Kong
CHCera W. Hassinan
Cera W. Hassinan
FGFlorian Gerstner
Florian Gerstner
JBJannik M. Buettner
Jannik M. Buettner
JPJeffrey B. Petigrow
Jeffrey B. Petigrow
CSCharlotte J. Sumner
Charlotte J. Sumner
Intercellular communication between axons and Schwann cells is critical for attaining the complex morphological steps necessary for axon maturation. In the early onset motor neuron disease spinal muscular atrophy (SMA), many motor axons are not ensheathed by Schwann cells nor grow sufficiently in radial diameter to become myelinated. These developmentally arrested motor axons are dysfunctional and vulnerable to rapid degeneration, limiting efficacy of current SMA therapeutics. We hypothesized that accelerating SMA motor axon maturation would improve their function and reduce disease features. A principle regulator of peripheral axon development is neuregulin 1 type III (NRG1-III). Expressed on axon surfaces, it interacts with Schwann cell receptors to mediate axon ensheathment and myelination. We examined NRG1 mRNA and protein expression levels in human and mouse SMA tissues and observed reduced expression in SMA spinal cord and in ventral, but not dorsal root axons. To determine the impact of neuronal NRG1-III overexpression on SMA motor axon development, we bred NRG1-III overexpressing mice to SMA∆7 mice. Neonatally, elevated NRG1-III expression increased SMA ventral root size as well as axon segregation, diameter, and myelination resulting in improved motor axon conduction velocities. NRG1-III was not able to prevent distal axonal degeneration nor improve axon electrophysiology, motor behavior, or survival of older mice. Together these findings demonstrate that early SMA motor axon developmental impairments can be ameliorated by a molecular strategy independent of SMN replacement providing hope for future SMA combinatorial therapeutic approaches.

10 July 2025 in JMIR Serious Games
Verified
Journal Article
Open access
SASpencer A Arbuckle
Spencer A Arbuckle
AKAnna Sophie Knill
Anna Sophie Knill
MCMichelle H Chan-Cortés
Michelle H Chan-Cortés
GRGabriela Rozanski
Gabriela Rozanski
AFAnastasia Elena Ford
Anastasia Elena Ford
MBMeret Branscheidt
Meret Branscheidt
Background: Accumulating evidence and medical guidelines recommend high-dose neurorehabilitation for recovery after stroke. The reality, however, is that most patients receive a fraction of this dose, with therapist availability and costs of delivery being major implementational barriers. Objective: This study aimed to explore a potential solution by conducting a retrospective analysis of a real-world enhanced clinical service that used gamified self-training technologies at home under remote therapist supervision. Methods: Data from 17 patients who completed a 12‐18 week full-body, high-dose neurorehabilitation program entirely at home were analyzed. Program delivery relied primarily on patients training independently (asynchronously) with the MindMotion GO (MindMaze) gamified-therapy solution. Accompanying telerehabilitation training sessions with a therapist occurred weekly while therapists used a web application to continuously monitor and manage the program remotely. Effectiveness of the program was assessed through measured active training time, a measure that more closely reflects delivered dosage as opposed to scheduled dose. Patient recovery was evaluated with standardized impairment and functional clinical measures and patient self-reported outcome measures. Finally, a cost model was computed to evaluate the resource efficiency of the program. Results: Patients maintained high training adherence throughout the program and reached an average total active training time of 39.7 (SD 21.4) hours, with the majority delivered asynchronously (mean 82.2%, SD 10.8%). Patients improved in both upper-limb (Fugl-Meyer Upper Extremity, mean 6.4, SD 5.1; P<.001) and gait and balance measures (Functional Gait Assessment, mean 3.1, SD 2.6; P<.001; Berg Balance Scale, mean 6.1, SD 4.4; P<.001). Overall, the program was viewed very favorably among patients who completed a post-program survey, with 73.7% (14/19) of respondents being satisfied or very satisfied, while 63.2% (12/19) of respondents reported subjective improvements in physical abilities. Per-patient therapist costs approximated US $338, representing a resource-efficient alternative to delivering the same dose via one-on-one in-person training sessions (US $1903). Conclusions: This work demonstrates effective high-dose neurorehabilitation delivery via gamified therapy technologies at home. The approach shows that training time can be successfully decoupled from therapist-presence without compromising adherence, outcomes, or patient satisfaction over an extended program period. Given growing concerns over therapist availability and increasing health care costs, this resource-efficient approach can help achieve medical guidelines and complement existing clinic-based approaches.

10 October 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SASpencer A. Arbuckle
Spencer A. Arbuckle
AKAnna Sophie Knill
Anna Sophie Knill
GRGabriela Rozanski
Gabriela Rozanski
MCMichelle Chan-Cortés
Michelle Chan-Cortés
AFAnastasia Elena Ford
Anastasia Elena Ford
MBMeret Branscheidt
Meret Branscheidt
Accumulating evidence and medical guidelines recommend high-dose neurorehabilitation for recovery after stroke. Unfortunately, most patients receive a fraction of this dose, with therapist availability and costs of delivery being major implementational barriers. To explore a potential solution, we conducted a retrospective analysis of a real-world enhanced clinical service that used gamified self-training technologies at home under remote therapist supervision. Data from 17 patients who completed a 12-18 week full-body, high-dose neurorehabilitation program entirely at home were analyzed. Program delivery relied on patients independently training (asynchronously) with the MindMotion GO gamified-therapy solution. Accompanying telerehabilitation sessions with a therapist occurred weekly while therapists used a web application to monitor and manage the program remotely. Patients maintained high training adherence throughout and reached an average total Active Training Time—a measure more closely reflecting delivered versus scheduled dose—of 39.7±21.4 hours, with the majority (82.2±10.8%) delivered asynchronously. Patients improved in both upper-limb (Fugl-Meyer, +6.4±5.1; p< 0.01) and gait and balance measures (Functional Gait Assessment, +3.1±2.6; p< 0.01; Berg Balance Scale, +6.1±4.4; p< 0.01). Most experienced subjective improvements in physical abilities and overall satisfaction. Per-patient therapist costs approximated 338 USD, representing a resource-efficient alternative to delivering the same dose in-person (1903 USD). This work demonstrates effective high-dose neurorehabilitation delivery via gamified therapy technologies at home and shows that training time can be successfully decoupled from therapist-presence without compromising adherence, outcomes, or patient satisfaction. Given growing concerns over therapist availability and increasing health care costs, this resource-efficient approach can help achieve medical guidelines and complement existing clinic-based approaches.